Bayer/Onyx Nexavar Fails Phase III Melanoma Trial

Onyx is continuing its melanoma program despite sorafenib’s failure to show a progression-free survival benefit in an advanced melanoma study.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet